RGNX REGENXBIO Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGNX

Price (delayed)

$14.33

Market cap

$705.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.87

Enterprise value

$678.08M

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, ...

Highlights
The quick ratio has increased by 40% since the previous quarter and by 2.9% year-on-year
REGENXBIO's debt has decreased by 6% YoY and by 2.3% QoQ
The equity has grown by 25% from the previous quarter but it has contracted by 16% YoY
RGNX's gross profit is down by 26% year-on-year and by 7% since the previous quarter
The company's revenue fell by 21% YoY and by 3.9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.regenxbio.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of RGNX
Market
Shares outstanding
49.26M
Market cap
$705.84M
Enterprise value
$678.08M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.63
Price to sales (P/S)
7.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.82
Earnings
Revenue
$86.73M
EBIT
-$254.22M
EBITDA
-$236.9M
Free cash flow
-$198.64M
Per share
EPS
-$5.87
Free cash flow per share
-$4.34
Book value per share
$8.79
Revenue per share
$1.9
TBVPS
$13.76
Balance sheet
Total assets
$629.22M
Total liabilities
$238.55M
Debt
$87.25M
Equity
$390.67M
Working capital
$285.24M
Liquidity
Debt to equity
0.22
Current ratio
3.59
Quick ratio
3.24
Net debt/EBITDA
0.12
Margins
EBITDA margin
-273.2%
Gross margin
56.9%
Net margin
-300%
Operating margin
-306.5%
Efficiency
Return on assets
-41.3%
Return on equity
-70.7%
Return on invested capital
-48.1%
Return on capital employed
-49%
Return on sales
-293.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGNX stock price

How has the REGENXBIO stock price performed over time
Intraday
-0.42%
1 week
13.91%
1 month
24.5%
1 year
-21.22%
YTD
-20.17%
QTD
22.48%

Financial performance

How have REGENXBIO's revenue and profit performed over time
Revenue
$86.73M
Gross profit
$49.34M
Operating income
-$265.83M
Net income
-$260.15M
Gross margin
56.9%
Net margin
-300%
RGNX's operating margin is down by 30% year-on-year and by 3.2% since the previous quarter
RGNX's gross profit is down by 26% year-on-year and by 7% since the previous quarter
REGENXBIO's net margin has decreased by 22% YoY and by 2.7% QoQ
The company's revenue fell by 21% YoY and by 3.9% QoQ

Growth

What is REGENXBIO's growth rate over time

Valuation

What is REGENXBIO stock price valuation
RGNX P/E details
P/E
N/A
P/B
1.63
P/S
7.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.82
RGNX's EPS is up by 6% year-on-year and by 2.5% since the previous quarter
RGNX's P/B is 37% below its 5-year quarterly average of 2.6 and 29% below its last 4 quarters average of 2.3
The equity has grown by 25% from the previous quarter but it has contracted by 16% YoY
The price to sales (P/S) is 37% lower than the 5-year quarterly average of 12.0 and 16% lower than the last 4 quarters average of 9.0
The company's revenue fell by 21% YoY and by 3.9% QoQ

Efficiency

How efficient is REGENXBIO business performance
The ROE is down by 42% YoY and by 3.7% QoQ
The ROIC has contracted by 39% YoY and by 7% from the previous quarter
REGENXBIO's ROA has decreased by 31% YoY and by 3.3% from the previous quarter
RGNX's return on sales is down by 28% year-on-year and by 3% since the previous quarter

Dividends

What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGNX.

Financial health

How did REGENXBIO financials performed over time
RGNX's total assets is 164% greater than its total liabilities
The current ratio has grown by 40% from the previous quarter and by 3.8% YoY
The quick ratio has increased by 40% since the previous quarter and by 2.9% year-on-year
REGENXBIO's debt is 78% lower than its equity
The equity has grown by 25% from the previous quarter but it has contracted by 16% YoY
RGNX's debt to equity is down by 24% since the previous quarter but it is up by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.